Research programme: anticancer therapeutics - Penrose TherapeuTx
Latest Information Update: 30 Nov 2020
At a glance
- Originator Penrose TherapeuTx
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer; Pancreatic cancer
Most Recent Events
- 29 Nov 2020 Research programme: anticancer therapeutics - Penrose TherapeuTx is available for licensing as of 23 Nov 2020. https://penrosetherapeutx.com/about-us/collaborations/ (Penrose TherapeuTx website, November 2020)
- 23 Nov 2020 Preclinical trials in Colorectal cancer in USA (unspecified route) before November 2020
- 23 Nov 2020 Preclinical trials in Pancreatic cancer in USA (unspecified route) before November 2020